Bardella, et al. investigated 59 patients with hypertransaminasemia and NAFLD, and 38 (64%) were diagnosed with NASH by anti-EMA and anti-tTG antibodies. Here, TGM2 is linked to metabolic dysfunction-associated steatotic liver disease.